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Purpose: Hypoxia is a common phenomenon encountered in solid cancers, leading to chemo­
therapy resistance and therefore to aggressiveness of the disease. The homeostatic response 
to hypoxia is mediated by hypoxia­inducible factor­1 (HIF­1). The aim of this study was to 
investigate the impact of HIF1α in patients with primary epithelial ovarian cancer.
Methods: In this multicentric study, 275 patients with advanced primary epithelial ovarian 
cancer were included. All patients underwent cytoreductive surgery with maximal surgical effort 
and adjuvant platinum­based chemotherapy. HIF1α expression was analyzed in tissue lysates, 
using an enzyme­linked immunosorbent assay.
Results: HIF1α was detected in 79.3% of the tissue samples. Patients with increased 
HIF1α expression (cutoff: 80 pg/mg protein) in tumoral tissue lysates were more likely to 
have less favorable survival. HIF1α (P=0.009, hazard ratio [HR] 2.505, 95% confidence 
interval [95% CI] 1.252–5.013) together with International Federation of Gynecology and 
Obstetrics (III versus IV) (P=0.013, HR 0.540, 95% CI 0.332–0.878), histology (P=0.007, 
HR 2.748, 95% CI 1.315–5.743), presence of peritoneal carcinomatosis (P=0.014, HR 2.176, 
95% CI 1.170–4.046), residual tumor mass (P=0.017, HR 1.641, 95% CI 1.091–2.468), and 
response to platinum­based chemotherapy (P,0.001, HR 8.131, 95% CI 5.13–12.88) were 
independent prognosis factors for overall survival. The independent prognostic factors 
for  progression­free survival were International Federation of Gynecology and Obstetrics 
stage (P=0.01), histological subtypes (P=0.016), and presence of peritoneal carcinomatosis 
(P,0.05).
Conclusion: HIF1α overexpression in ovarian cancer is associated with poor overall survival, 
underlining the importance of hypoxia in this angiogenesis driven disease.
Keywords: HIF1α, surgical outcome, platinum response, survival, primary epithelial ovarian 
cancer, predictive factors
Introduction
Ovarian cancer is the leading cause of death from gynecological malignancies, with 
more than half of patients being diagnosed in the advanced stage. The overall 5­year 
survival rate is around 40% in International Federation of Gynecology and Obstetrics 
(FIGO) stages III/IV and 90% in FIGO stage I.1
The current standard of treatment for primary ovarian cancer is the combination of 
optimal cytoreductive surgery and platinum­based chemotherapy. Despite state of the 
art treatment, more than 50% of the patients will relapse and consequently die from this 
disease.2 A curative approach is only possible in the primary situation. The aim of targeted 





therapy is to prolong the tumor­free status achieved after the 
primary treatment. Recent data showed that some antiangiogenic 
therapies, eg, bevacizumab, are able to prolong progression­free 
survival, thus no improvement in overall survival has been shown 
yet.3,4 There is an urgent need to identify new targets, and also 
biomarkers able to predict platinum response.
No macroscopic residual tumor mass after cytoreductive 
surgery is one of the major prognostic and predictive factors. 
Despite radical surgery, maximal tumor reduction cannot always 
be achieved. A neoadjuvant approach could have a benefit in 
this subgroup of patients, although data are controversial.5–8 
Nevertheless, there are no effective biomarkers to predict surgi­
cal outcome in primary ovarian cancer patients.
HIF1α has been reported to be an important predictor 
of tumor progression for several types of solid cancers.9–13 
HIF1α is a major regulator of cell adaptation to hypoxic stress 
and plays a critical role in oncogenesis and angiogenesis.14 
This protein regulates the transcription of a number of genes 
involved in diverse biological functions such as proliferation, 
migration, invasion, apoptosis, and angiogenesis.
Immunohistochemical analysis of human cancer biop­
sies has shown that HIF1α is overexpressed in several solid 
malignancies, including breast, colon, lung, gastric, skin, 
and renal carcinomas, compared with their respective normal 
tissues.15,16
Like other tumors, overexpression of HIF1α has been 
detected in epithelial ovarian cancer.15 Data regarding the 
clinical impact of HIF1α in ovarian cancer is still limited. 
Although HIF1α is detected in all epithelial ovarian cancer 
histological subtypes, higher HIF1α expression in clear­cell 
carcinomas has been reported.17,18
The role of HIF1α in the development of new targeted 
therapies has been suggested by recent studies.19,20 Nakai 
et al stated that HIF1α­expressing tumors had a signifi­
cantly higher response rate to postoperative platinum­based 
 chemotherapy than tumors without HIF1α expression.21
However, the prognostic significance of HIF1α overex­
pression in ovarian cancer is still controversial.21–24 Until now, 
only limited data exist regarding the HIF1α predictive value 
in epithelial ovarian cancer.
The aim of this study was to investigate the impact of 
HIF1α expression in predicting surgical outcome, platinum 
response, and survival in patients with advanced primary 
epithelial ovarian cancer.
Patients and methods
This analysis was performed within the Sixth Framework 
Program European project “Ovarian Cancer – Diagnosis of 
a Silent Killer” (OVCAD). At five comprehensive centers 
for ovarian cancer treatment, 275 patients with advanced 
primary epithelial ovarian cancer (FIGO stage II–IV) were 
enrolled.
All patients gave their written informed consent before 
tissue samples were collected. Patients were recruited 
from 2005–2008 in the Department of Gynecology at 
Charité – Medical University Berlin (Berlin, Germany), 
Department of Gynecologic Oncology, University  Hospital 
Leuven  (Leuven, Belgium), Department of Obstetrics and 
 Gynecology,  Medical University of Vienna (Vienna,  Austria), 
Department of Gynecology, University Medical Center 
Hamburg­ Eppendorf (Hamburg, Germany), and Department 
of Gynecology and Obstetrics, Innsbruck  Medical University 
(Innsbruck, Austria). This study was approved by each local 
ethics committee (EK207/2003, ML2524, HEK190504, 
EK366, and EK260).
Only patients with histologically confirmed ovarian 
 cancer were included in the study. Due to better prognosis 
and sometimes different therapy strategies, FIGO stage I 
patients were excluded. All patients underwent cytoreductive 
surgery with maximal surgical effort and platinum­based 
chemotherapy. Inclusion and exclusion criteria for the study 
were reported in a recent publication.25 An online database 
was used for the documentation of clinical, histopathological, 
and follow­up data. Residual tumor load was defined as nega­
tive if macroscopically absent. Overall survival was defined 
as the time from diagnosis of ovarian cancer to tumor­related 
death or last contact. Progression­free survival was defined as 
the interval from diagnosis to progression of disease or death, 
whereby progression was defined as an increase in the nadir 
serum CA­125 level of at least two samples according to 
the Gynecological Cancer Intergroup criteria or radiological 
diagnosis according to the Response Evaluation Criteria in 
Solid Tumors (RECIST) criteria.
Documentation of clinical data
The tumor spread within the abdominal cavity was 
documented prospectively using the Intraoperative 
 Mapping of Ovarian cancer – “IMO” tool.26 The documen­
tation of residual tumor mass was also assessed prospec­
tively at the end of the surgery with an interview with the 
main surgeon. All data were documented in a validated 
online database.
The FIGO 2006 classification was used for clinical stag­
ing, and the Gynecologic Oncology Group criteria were used 
for histologic grading.27 Response to treatment and diagnosis 
of recurrence was determined according to RECIST criteria 
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or according to CA­125 variations (Gynecological Cancer 
Intergroup criteria) during follow­up.27,28
Response to f irst­line chemotherapy was def ined 
according to the last time patients received platinum­based 
compounds. Patients developing relapse within the first 
6 months after platinum based chemotherapy were classi­
fied as platinum­resistant; patients developing relapse after 
6 months or more were classified as responders.29
collection of tumor tissue
Tumor tissue was removed from the patients during surgery 
and prior to chemotherapy treatment. Samples were snap 
frozen and stored in liquid nitrogen. At a later time, the tissue 
was processed to obtain lysate for protein measurement.
About 30 mg tumor tissue was homogenized with a 
Mikro­Dismembrator and lysed in 1 mL Nucleic Acid 
 Purification Lysis Solution (Thermo Fisher Scientific, 
Waltham, MA, USA).
hiF1α enzyme-linked immunosorbent  
assay (elisa)
HIF1α expression in tissue lysates was measured using the 
HIF1α ELISA kit (R&D Systems, Inc., Minneapolis, MN, 
USA) according to the manufacturer’s protocol. The assay 
was performed in duplicate for the calibrators, controls, and 
patient samples. The appropriate controls were within the 
ranges provided by the manufacturer.
statistical analysis
The clinical data were collected and entered in an online 
database. The statistical analysis was performed using IBM® 
SPSS® Statistics 21.0 (IBM Corporation, Armonk, NY, USA) 
at Charité – Medical University Berlin.
The prognostic factors used in the survival analysis were 
as follows: age at first diagnosis, FIGO stage, histological 
subtype, histological grade, presence and volume of ascites, 
residual tumor mass after surgery, peritoneal dissemination, 
and responses to platinum­based chemotherapy.
Kruskal–Wallis test, Spearman’s rank correlation, 
 Kendall’s tau, and Mann–Whitney U test were used to assess 
the associations between HIF1α and other variables.
Receiver operating characteristic curve analysis was 
performed to evaluate the predictive accuracy of HIF1α 
expression for discriminating patients with maximal versus 
suboptimal residual tumor mass after surgery and platinum 
responders versus nonresponders.
Median survival and 95% confidence intervals (95% CI) 
were estimated according to the Kaplan–Meier method. 
The log­rank tests were used for univariate statistical 
comparisons and the Cox proportional hazard model was 
used to evaluate significant predictors of survival. Adjusted 
hazard ratios (HR) and 95% CI for prognostic factors were 




Most of the patients (86.2%) were diagnosed with serous 
ovarian cancer. Optimal debulking, ie, no evidence of mac­
roscopic tumor residuals, was reported in more than 60% of 
the patients. Patients’ characteristics are presented in Table 1, 
and are reported in greater detail elsewhere.25
Table 1 Patient’s clinical and pathologic characteristics
Parameter Primary ovary cancer
Ovarian cancer samples included to the 
multicenter study, n (%)
275 (100.0)
age at time of diagnosis, median (range),  
years
58 (18–85)
histological type, n (%)
 serous 237 (86.2)
 endometrioid 13 (4.7)
 Mixed/others* 25 (9.1)
Tumor stage, n (%)
 FigO ii 15 (5.4)
 FigO iii 212 (77.1)
 FigO iV 48 (17.5)
lymph node status, n (%)
 n0 65 (23.6)
 n1 143 (52)
 nx 67 (24.4)
Distant metastatic spread, n (%)
 M0 142 (51.6)
 M1 49 (17.8)
 Mx 84 (30.5)
grading, n (%)
 Well differentiated 10 (3.6)
 Moderately differentiated 64 (23.3)
 Poorly differentiated 200 (72.7)
 Unknown 1 (0.4)
ca-125 level, n (%) 258 (93.8)
 Preoperatively, median (range), U/ml 1,500.24 (7–37,820)
ascites volume, n (%)
 none 66 (24)
 #500 ml 110 (40)
 .500 ml 100 (36)
Peritoneal carcinomatosis, n (%)
 Yes 186 (67.6)
 no 89 (32.4)
Postoperative residual tumor mass, n (%)
 Macroscopic tumor free 188 (68.4)
 #1 cm 48 (17.5)
 .1 cm 38 (13.8)
 Missing 1 (0.4)
Note: *eleven mixed, nine undifferentiated, and two clear-cell carcinomas.
Abbreviation: FigO, international Federation of gynecology and Obstetrics.






Expression of HIF1α was confirmed in 218 (79.3%) 
patients. No expression of HIF1α was observed in 57 tissue 
samples (20.7%). The median HIF1α expression was 56.8 
(range 0–1,492.31) pg/mg protein.
correlation with classical  
prognostic factors
No statistically significant association between HIF1α 
expression and clinical prognostic factors such as age 
(P=0.238), volume of ascites (P=0.866), FIGO stage 
(P=0.0896), and grading (P=0.152) was found.
Levels of HIF1α were higher in patients presenting peri­
toneal carcinomatosis and mucinous and mixed histology, 
although this correlation retained no statistical significance 
(P=0.065 and P=0.071, respectively).
There was no correlation between HIF1α and residual 
tumor mass after cytoreductive surgery (P=0.342, area 
under the curve 0.555, 95% CI 0.471–0.639) or response to 
platinum­based chemotherapy (P=1, area under the curve 
0.499, 95% CI 0.413–0.586) (Table 2).
survival analysis
The median follow­up time for patients was 37 months, 
ranging from 1–69 months; 194 patients developed 
 recurrent disease and 134 patients died from ovarian 
cancer.
In order to analyze the role of HIF1α for survival, the 
lower and upper quintiles were used as cutoff values. Using 
the cutoff values of 15 pg/mg protein and 80 pg/mg protein, 
it could be shown that patients presenting HIF1α tissue con­
centrations higher than 80 pg/mg protein would have a shorter 
overall survival, although this association was not significant 
within the univariate analysis. When multivariate analy­
sis was performed, HIF1α concentrations over 80 pg/mg 
protein remained an independent prognostic biomarker for 
overall survival (P=0.009, HR 2.505, 95% CI 1.252–5.013) 
(Figure 1) together with FIGO (III versus IV) (P=0.013, 
HR 0.540, 95% CI 0.332–0.878),  histology (mixed versus 
serous versus endometrioid) (P=0.007, HR 2.748, 95% 
CI 1.315–5.743), presence of peritoneal  carcinomatosis 
(P=0.014, HR 2.176, 95% CI 1.170–4.046), residual tumor 
mass (present versus absent macroscopically) (P=0.017, HR 
1.641, 95% CI 1.091–2.468), and response to platinum­based 
chemotherapy (P,0.001, HR 8.131, 95% CI 5.13–12.88).
FIGO stage (P=0.001, HR 0.478, 95% CI 0.314–0.726), 
presence of peritoneal carcinomatosis (P,0.001, HR 2.620, 
95% CI 1.704–4.027), and histology (P=0.021, HR 2.306, 
95% CI 1.137–4.677) were the only independent predictive 
factors for progression­free survival.
Discussion
This study analyzed the role of HIF1α in primary ovarian 
cancer. The results showed that patients having tumors that 
overexpress HIF1α transcription factor (cutoff 80 pg/mg 
protein) are presenting a poorer prognosis.
One of the major bottlenecks in ovarian cancer 
 management is the development of platinum resistance with 
Table 2 correlation with clinical prognostic factors
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Figure 1 hiF1α expression and overall survival (P=0.009, hazard ratio 2.505, 95% 
confidence interval 1.252–5.013).




impact of hiF1α in patients with primary epithelial ovarian cancer
subsequently increased mortality. The development of new 
targeted, especially antiangiogenic, drugs has translated into 
prolonged progression­free survival without evidence of a 
positive impact on overall survival. The inhibition of neoan­
giogenesis in ovarian cancer leads to a certain hypoxia of the 
tumoral cells, and therefore increases apoptosis of tumoral 
cells. There are no in sufficient data to show a benefit in 
overall survival for patients being treated with antiangiogenic 
drugs. This might be caused by the capability of tumor cells 
to resist even hypoxic conditions.
One of the mechanisms of chemotherapy resistance in 
solid tumors is the ability to develop a microenvironment 
caused by a poor and inefficient vascular supply.30 The 
presence of hypoxia has been shown to be a marker for 
poor  prognosis in many cancer types. The resistance 
to conventional chemotherapeutical drugs is caused by 
hypoxia­induced reduction in cell proliferation and also 
by the fact that hypoxic tumor cells reside some distance 
from the blood vessels, and therefore the drugs won’t be 
able to reach their target.31,32 The homeostatic response 
to hypoxia is mediated by the transcription factor HIF1α, 
which is unstable in well­oxygenated tissue but becomes 
stable under hypoxic conditions.33 Due to hypoxic condi­
tions in tumoral tissue, as described  previously, HIF1α is 
an important mediator for tumor invasion, metastasis, and 
chemotherapy resistance.34
This study showed that HIF1α expression was indepen­
dent of FIGO stage, age, and grading. Mucinous and mixed 
epithelial carcinomas showed increased levels of HIF1α, 
although this association didn’t reach statistical significance. 
Previously published data showed that clear­cell carcinomas 
exhibit higher HIF1α levels than serous, mucinous, or endo­
metrioid tumors.35,36 Other studies suggest that HIF1α might 
be overexpressed in serous ovarian cancer.24 The difference 
in the current results could be caused by low numbers of 
well­differentiated (3.6%) and non­serous ovarian cancer 
patients included within the OVCAD study. More than 
that, differences in ethnicity might cause differences in the 
molecular biology of ovarian cancer. It is well known that 
clear­cell ovarian cancer is more often encountered in Asian 
women compared to Caucasian women, and the clinical 
course of the disease is different. Clinical studies showed 
that chemotherapy or targeted therapy drugs are associated 
with different response rates and adverse effects in Caucasian 
and Asian populations.37
Results similar to the current study were published 
by Nakayama et al, who reported that HIF1α levels were 
independent of clinical stage, age and histological sub­
types.38 HIF1α expression was reported to be significantly 
stronger in good differentiated ovarian cancer.17 The current 
results showed no significant correlation between HIF1α 
tissue expression and histological grading, which might be 
explained by the low number of well­differentiated (G1) 
ovarian cancers included in this study. There was also no 
significant influence of HIF1α expression on response to 
platinum­based chemotherapy, this being in accordance 
with some existing results.17 However, Nakai et al reported 
that  tumors expressing higher HIF1α more likely respond to 
platinum­based chemotherapy compared with tumors with no 
or poor HIF1α expression.21 The current study analyzed the 
expression of HIF1α in 275 patients with FIGO stage II–IV, 
but Nakai et al’s study only included 52 stage III–IV epithelial 
ovarian cancer patients.
HIF1α increased tissue values were associated with 
shorter progression­free survival, but this was not statistically 
significant, which agrees with recent studies.22,23 Daponte 
et al observed that the median progression­free survival of 
HIF1α­positive patients was shorter, but not statistically 
significant.22 In lung and colorectal carcinomas, HIF1α had 
no impact on patient survival, but overexpression of HIF2α 
was a prognostic indicator.39,40 In ovarian carcinomas, Birner 
et al showed that HIF1α overexpression alone was not a 
prognostic indicator and became a strong prognostic marker 
in combination with functional p53 protein.17
Conclusion
The current study showed that HIF1α tissue expression 
might impact the overall survival in primary ovarian cancer 
patients treated by cytoreductive surgery and platinum­based 
chemotherapy. No correlation between HIF1α tissue expres­
sion and platinum response and no significant statistical dif­
ference between HIF1α expression in different histological 
subtypes was found. Further studies analyzing the role of this 
transcriptional factor in a larger prospective cohort of patients 
are warranted. Studies analyzing the HIF1α distribution 
within tumor tissue using immunochemistry are needed.
Drugs interfering with the HIF1α pathway, such as 
ganetespib,41 are currently under evaluation in clinical 
 studies. Targeting HIF1α might be a way to improve survival 
in ovarian cancer patients.
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